FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer's disease

NOVÁK, P., SCHMIDT, R., KONTSEKOVÁ, E., KOVÁČECH, B., SMOLEK, T., KATINA, Stanislav, FIALOVÁ, L., PRČINA, M., PARRAK, V., DAL-BIANCO, P., BRUNNER, M., STAFFEN, W., RAINER, M., ONDRUŠ, M., ROPELE, S., SMÍŠEK, M., SIVAK, R., ŽILKA, N., WINBLAD, B., NOVÁK, M. FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer's disease. Alzheimers Research & Therapy. 2018, 10), 108. E-ISSN 1758-9193. Dostupné z: doi: 10.1186/s13195-018-0436-1